Latest & greatest articles for amiodarone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on amiodarone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on amiodarone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for amiodarone

41. Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery

Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Economic analysis of intravenous plus oral amiodarone, atrial septal pacing, and both strategies to prevent atrial fibrillation after open heart surgery Reddy P, Kalus J S, Caron M F, Horowitz (...) compared. The alternative strategies were amiodarone, pacing, amiodarone plus pacing, and placebo. Patients received a loading dose of amiodarone (1,050 mg intravenously) within 6 hours after surgery, followed by oral amiodarone (400 mg 3 times daily) or matching placebo on postoperative days 1 to 4. Atrial septic pacing consisted of the use of a single pacing wire and one pacemaker box. It was started within 6 hours after surgery and was continued for 96 hours. Type of intervention Secondary

NHS Economic Evaluation Database.2004

42. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis

Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P CRD summary This well reported review compared amiodarone with placebo (...) or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Even though the onset of conversion was delayed, the efficacy of amiodarone was similar at 24 hours compared with class Ic drugs. The conclusions reached by the authors seem valid and the limited generalisability of the findings was acknowledged. Authors' objectives To conduct a meta-analysis comparing amiodarone with placebo or class Ic drugs for the cardioversion of recent-onset atrial fibrillation (AF). Searching

DARE.2003

43. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis

Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis Letelier L M, Udol K, Ena J, Weaver B, Guyatt G H CRD summary This review assessed the effectiveness of amiodarone in treating atrial fibrillation (AF). In this thorough and well-conducted review (...) , the authors concluded that amiodarone is effective in treating AF in a wide range of patients. However, as information on adverse events was limited, further studies are required. Authors' objectives To assess the effect of amiodarone in converting atrial fibrillation (AF) to sinus rhythm. Searching MEDLINE (January 1966 to February 2001), EMBASE (January 1980 to September 2000), the Cochrane Controlled Trials Register (Issue 3, 2000) and Best Evidence (January 1991 to September 2000) were searched using

DARE.2003

44. Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications

Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications Amiodarone versus implantable defibrillator (AMIOVIRT): background, rationale, design, methods, results and implications Wijetunga M, Strickberger S A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of amiodarone versus implantable defibrillator (ICD) therapy in patients with non-ischaemic dilated cardiomyopathy (NIDCM) and asymptomatic non-sustained ventricular tachycardia (NSVT). Amiodarone was initiated at a dose of 800 mg/day for the first week, followed

NHS Economic Evaluation Database.2003

45. Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT

Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT Amiodarone versus implantable cardioverter-defibrillator: randomized nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia (...) - AMIOVIRT Strickberger S A, Hummel J D, Bartlett T G, Frumin H I, Schuger C D, Beau S L, Bitar C, Morady F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of amiodarone with an implantable cardioverter

NHS Economic Evaluation Database.2003

46. Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection

Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Low-dose oral amiodarone prophylaxis reduces atrial fibrillation after pulmonary resection Lanza L A, Visbal A I, DeValeria P A, Zinsmeister A R, Diehl N N, Trastek V F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief (...) summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of low-dose oral amiodarone (LDOA) as prophylactic treatment for atrial fibrillation (AF) after pulmonary resection. LDOA comprised 200 mg by mouth every 8 hours. Treatment was started after recovery from general anaesthesia and was discontinued at dismissal. Type of intervention Secondary prevention. Economic study type

NHS Economic Evaluation Database.2003

47. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials

Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials Hilleman D E, Spinler S A Authors' objectives To evaluate the efficacy and safety of intravenous amiodarone for conversion (...) of recent-onset atrial fibrillation (AF). Searching MEDLINE was searched from January 1975 to March 2001 for studies published in the English language. The search terms were 'atrial fibrillation', 'amiodarone' and 'cardioversion'. Pertinent review articles and the reference lists in the identified studies were examined for additional studies. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible. Specific interventions included

DARE.2002

48. Amiodarone vs sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis

Amiodarone vs sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis Amiodarone vs sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis Amiodarone vs sotalol as prophylaxis against atrial fibrillation/flutter after heart surgery: a meta-analysis Wurdeman R L, Mooss A N, Mohiuddin S M, Lenz T L Authors' objectives To compare the efficiency of sotalol versus amiodarone in preventing the occurrence (...) . Specific interventions included in the review The prophylactic administration of either sotalol or amiodarone to patients, from between 13 (plus or minus 7) days before undergoing open-heart surgery (CABG with or without valve replacement) to 6 hours after. The included studies reported a range of drug regimens, further details of which are provided in the article. Trials including any other anti-arrhythmic agents were excluded from the review. The control groups received either active placebo

DARE.2002

49. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial

Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial Lumer G B, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, Thibault B, Dubuc M, Gagne P, Nattel S Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Low-dose amiodarone was compared with other first-line therapy (sotalol or propafenone) for the treatment of atrial fibrillation (AF). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2002

50. An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery

An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery An economic analysis of amiodarone versus placebo for the prevention of atrial fibrillation after open heart surgery Reddy P, Dunn A B, White C M, Tsikouris J P, Giri S, Kluger J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated prophylaxis with oral amiodarone in patients undergoing open heart surgery. The doses used are described in the 'Study Sample' field. Type of intervention Prophylaxis, (primary prevention). Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2002

51. Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation

Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Cost-effectiveness of targeting patients undergoing cardiac surgery for therapy with intravenous amiodarone to prevent atrial fibrillation Mahoney E M, Thompson T D, Veledar E, Williams J, Weintraub W S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of prophylactic intravenous (IV) amiodarone therapy for the prevention of atrial fibrillation (AF) in patients undergoing cardiac surgery. Type of intervention Secondary prevention. Economic study type

NHS Economic Evaluation Database.2002

52. Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis

Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis Pazdral T E, Burton J H, Strout T D, Bradshaw J R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of amiodarone (150-mg vial) in a system-wide, rural prehospital treatment protocol for cardiac arrest patients was examined. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients identified by EMS personnel as presenting with a diagnosis of cardiac arrest. Patients

NHS Economic Evaluation Database.2002

53. Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting

Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary artery bypass grafting Effect of amiodarone +/- diltiazem +/- beta blocker on frequency of atrial fibrillation, length of hospitalization, and hospital costs after coronary (...) patients who had undergone coronary artery bypass grafting (CABG) was examined. The pathway was based on the administration of oral amiodarone, rate and rhythm control, cardioversion, and anticoagulation. Rate control, if needed, was mainly achieved with intravenous diltiazem and less often with a beta-blocker. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who had CABG and preoperative normal sinus

NHS Economic Evaluation Database.2002

54. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation

Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2002

55. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation.

Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. 11907287 2002 03 21 2002 03 29 2013 11 21 1533-4406 346 12 2002 Mar 21 The New England journal of medicine N. Engl. J. Med. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. 884-90 Lidocaine has been the initial antiarrhythmic drug treatment recommended for patients with ventricular fibrillation that is resistant to conversion by defibrillator shocks. We performed a randomized (...) trial comparing intravenous lidocaine with intravenous amiodarone as an adjunct to defibrillation in victims of out-of-hospital cardiac arrest. Patients were enrolled if they had out-of-hospital ventricular fibrillation resistant to three shocks, intravenous epinephrine, and a further shock; or if they had recurrent ventricular fibrillation after initially successful defibrillation. They were randomly assigned in a double-blind manner to receive intravenous amiodarone plus lidocaine placebo

NEJM2002

56. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. BACKGROUND: Clinical trials have shown that implantable cardioverter defibrillators (ICDs) improve survival in patients with sustained ventricular arrhythmias. OBJECTIVE: To determine the efficacy necessary to make prophylactic ICD or amiodarone therapy cost-effective in patients with myocardial infarction. DESIGN: Markov model-based cost utility analysis (...) . DATA SOURCES: Survival, cardiac death, and inpatient costs were estimated on the basis of the Myocardial Infarction Triage and Intervention registry. Other data were derived from the literature. TARGET POPULATION: Patients with past myocardial infarction who did not have sustained ventricular arrhythmia. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTIONS: ICD or amiodarone compared with no treatment. OUTCOME MEASURES: Life-years, quality-adjusted life-years (QALYs), costs

Annals of Internal Medicine2001

57. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction

Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction Sanders G D, Hlatky M A, Every N R, McDonald K M, Heidenreich P A, Parsons L S, Owens D (...) K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two prophylactic strategies for patients who had myocardial infarction (MI) were examined. The strategies were implantable cardioverter defibrillator (ICD) and amiodarone (AMIO

NHS Economic Evaluation Database.2001

58. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial.

Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. 11265951 2001 03 26 2001 04 12 2015 06 16 0140-6736 357 9259 2001 Mar 17 Lancet (London, England) Lancet Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. 830-6 Beta-blockers and amiodarone reduce (...) the frequency of atrial fibrillation after open-heart surgery but the effectiveness of oral amiodarone in older patients already receiving beta-blockers is unknown. We have assessed the efficacy of oral amiodarone in preventing atrial fibrillation in patients aged 60 years or older undergoing open-heart surgery. We did a randomised, double-blind placebo-controlled trial in which patients undergoing open-heart surgery (n=220, average age 73 years) received amiodarone (n=120) or placebo (n=100). Patients

Lancet2001

59. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. 10738049 2000 03 30 2000 03 30 2014 11 20 0028-4793 342 13 2000 Mar 30 The New England journal of medicine N. Engl. J. Med. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. 913-20 The restoration and maintenance of sinus rhythm is a desirable goal in patients with atrial fibrillation, because the prevention of recurrences can (...) improve cardiac function and relieve symptoms. Uncontrolled studies have suggested that amiodarone in low doses may be more effective and safer than other agents in preventing recurrence, but this agent has not been tested in a large, randomized trial. We undertook a prospective, multicenter trial to test the hypothesis that low doses of amiodarone would be more efficacious in preventing recurrent atrial fibrillation than therapy with sotalol or propafenone. We randomly assigned patients who had had

NEJM2000

60. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery

Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Reddy P, Richerson M, Freeman-Bosco L, Dunn A, White C M, Chow M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients undergoing CABG. Setting The setting was hospital

NHS Economic Evaluation Database.1999